Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

FDA Approves Sarilumab for pJIA

  |  Issue: August 2024  |  

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. Supplemental approval letter for pJIA for Kevzara (sarilumab) injection. U.S. Food & Drug Administration. 2024 Jun 10.
  2. Kevzara (sarilumab) injection. U.S. Food & Drug Administration. 2017 Jun 3.
  3. Supplement approval letter for PMR Kevzara (sarilumab) injection. U.S. Food & Drug Administration. 2023 Feb 28.
  4. Highlights of prescribing information: Kevzara (sarilumab) injection. U.S. Food & Drug Administration. 2024 Jun 10.
  5. Kevzara approved by FDA for the treatment of active polyarticular juvenile idiopathic arthritis [news release]. Sanofi. 2024 Jun 11.

Related Articles

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    MicroOne / shutterstock.com

    Rheumatology Drugs at a Glance, Part 2: Psoriasis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug option; others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and other medications used to…

    FDA Provides 2020 Rheumatology Drug Update

    Three FDA representatives discuss new drug indications, safety precautions and label changes, & an emergency program to rapidly evaluate existing immunomodulating therapies for use in COVID-19 patients.